NIH SBIR
NIH SBIR Letters of Support: Who Should Write Them and What to Include
Learn who should write NIH SBIR letters of support, what each letter should include, and how to document credible commitments.
Use letters of support to document commitments reviewers can evaluate
NIH SBIR letters of support help reviewers assess whether your startup can execute its proposed research. A strong letter connects an outside contributor, resource, or commercial relationship to a specific part of the project. For a diagnostic startup, that might mean access to well-characterized specimens. For a therapeutic company, it might mean a specialist’s commitment to advise on an animal model. For a research-tools developer, it might mean a laboratory’s agreement to evaluate prototype performance. Build your letter strategy around the commitments that make your research plan credible.
Start with the active NIH notice of funding opportunity and the application instructions it references. Requirements can vary by institute, application type, and funding mechanism. The PHS 398 Research Plan includes a Letters of Support attachment, while an opportunity may also specify requirements for commercialization-related evidence or other attachments. Confirm the permitted placement, content, and any limits before requesting letters. NIH reviewers assess the application against the opportunity’s review criteria, so each letter should substantiate something relevant to feasibility, expertise, access, or commercial potential. A collection of general endorsements contributes little usable evidence.
Choose signers who control the expertise or resources you need
Map your proposed aims to the people and organizations outside your company whose participation matters. Common signers include scientific collaborators, paid consultants, specimen providers, core facility directors, clinical site investigators, and prospective customers. Give priority to relationships that address a material execution risk. If your validation aim depends on archived human specimens, a letter from the organization controlling those specimens can establish their availability and the process for accessing them. If an assay requires specialized instrumentation, the facility responsible for scheduling access should confirm the relevant capabilities and anticipated availability.
Match the signer’s authority to the commitment. A principal investigator may be able to commit scientific effort within their role, while access to institutional data, licenses, or clinical infrastructure may require additional approvals. Ask the signer to distinguish resources they can commit directly from activities subject to institutional review. For a prospective customer, identify someone with relevant operational, purchasing, or technical evaluation responsibility. Their role should make clear why their assessment matters. One letter can cover several related contributions, but separate letters may be useful when different organizations independently control essential parts of the work.
Specify the contribution, timing, and conditions in each letter
Give each signer a short briefing package containing the project title, relevant aim, proposed contribution, project period, and any associated budget assumptions. Ask for a dated, signed letter on organizational letterhead where appropriate. Its substance should explain the writer’s relevant expertise, relationship to the company, specific role, and expected contribution. NIH application instructions call for consultant letters to include the rate or charge for consulting services and the anticipated hours per budget period. Those figures should agree with the budget justification. A collaborator’s letter should similarly describe their responsibilities and support the scope of work presented elsewhere in the application.
Use measurable details wherever the contributor can reasonably provide them. An illustrative specimen-provider letter might state: “Subject to institutional approvals and execution of a material transfer agreement, our biobank expects to provide approximately 40 archived plasma specimens meeting the study’s inclusion criteria during the first six months of the project.” The appropriate quantity depends on your study design and inventory. For a testing laboratory, useful details could include the assay, expected sample throughput, deliverables, and turnaround assumptions. State material conditions openly, including award-dependent participation, scheduling constraints, and required agreements. Specific conditions help reviewers judge whether the proposed timeline is realistic.
Separate scientific collaboration from customer and investor interest
Scientific support letters should establish how the research will happen. A clinical collaborator might describe expertise in the target population, involvement in protocol development, and the institution’s potential role in recruitment. A core facility might confirm access to a platform and the staff available to operate it. An academic collaborator might explain responsibility for a particular analysis. Keep these statements aligned with the Research Strategy, personnel documents, and any proposed subaward. When the work involves human participants or identifiable information, describe the expected institutional review and access process consistently with the application’s human subjects materials.
Customer, licensee, and investor letters serve a different purpose: they document the status and substance of commercial interest. A prospective customer can explain its current workflow, relevant performance requirements, and willingness to evaluate a product if those requirements are met. A potential licensee can describe the scope and stage of discussions. An investor can accurately characterize diligence activity or financing conditions. Use language that reflects the actual relationship. An agreement to evaluate a prototype, a conditional purchasing interest, and an executed purchase commitment carry different meanings. Place commercial letters according to the opportunity’s instructions, and connect their contents to the commercialization narrative wherever that narrative is required.
Check consistency and assemble the NIH attachment correctly
Maintain a letter tracker with the signer, organization, contribution, responsible company contact, draft status, and approval dependencies. Request letters once the aims and partner roles are stable, leaving time for institutional review. Before submission, compare every letter against the final application. Check consultant hours and rates, sample quantities, facility access, project dates, and collaborator responsibilities. Resolve discrepancies with the signer and obtain approval of the final wording. Letters should substantiate the research plan within NIH’s attachment rules; keep experimental methods and other required scientific content in their designated application sections.
For the standard Research Plan Letters of Support attachment, combine the letters into one PDF unless the opportunity provides different directions. Follow applicable NIH formatting requirements and inspect the uploaded file through your submission workflow, whether that uses ASSIST, an institutional system-to-system solution, or Grants.gov Workspace. Confirm that signatures, letterhead, and every page are readable. Keep executed agreements and supporting correspondence organized separately; resource access may still depend on contracts, approvals, or other arrangements beyond the letter itself. GrantUp’s PhD-level scientists and former federal reviewers can help connect partner commitments to a coherent NIH SBIR application. To discuss your project’s eligibility and application needs, book a free eligibility call with GrantUp.
Ready to turn this into a funded proposal?
Book a free 30-minute consultation with a senior grant consultant. We will check your eligibility, match you to the right program, and map out your submission timeline.
Learn more about our approach